Table 5.
Comparison of serum free fatty acids of Hepatitis B patients and controls
| Fatty acids | Controls (g/100 g) (n = 50) |
Patients (g/100 g) (n = 50) |
|---|---|---|
| C – 14:0 | 1.39 ± 0.6 | 1.61 ± 0.6 |
| C - 16: 0 | 21.91 ± 4.3 | 28.70 ± 4.5* |
| C - 18: 0 | 13.33 ± 5.9 | 18.60 ± 6.4* |
| C - 20: 0 | 0.44 ± 0.8 | 0.08 ± 0.2* |
| C – 24: 0 | 0.13 ± 0.4 | 0.12 ± 0.2 |
| C - 14: 1 | 0.19 ± 0.3 | 0.65 ± 0.3* |
| C - 16: 1 | 2.80 ± 1.2 | 3.39 ± 0.3 |
| C - 18: 1 | 21.60 ± 4.5 | 21.52 ± 3.7 |
| C - 22: 1 | 1.75 ± 1.2 | 1.37 ± 0.8 |
| C – 24: 1 | 0.11 ± 0.1 | 0.11 ± 0.3 |
| C - 18: 2 | 28.71 ± 5.1 | 19.50 ± 3.4* |
| C - 18: 3 | 0.60 ± 1.0 | 0.08 ± 0.2* |
| C - 20: 3 | 0.55 ± 0.8 | 0.02 ± 0.05* |
| C - 20: 4 | 5.67 ± 2.1 | 3.04 ± 1.1* |
| C - 20: 5 | 0.81 ± 1.3 | 0.03 ± 0.1* |
| C - 22: 5 | 0.22 ± 0.2 | 0.05 ± 0.1* |
| C - 22: 6 | 0.18 ± 0.2 | 0.63 ± 0.8* |
Values are mean ± standard deviation,*shows significant difference from Hepatitis B patients with comparison of healthy controls a p < 0.05 (t-test). myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid (C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosahexaenoic acid (DHA (C22:6), lignoceric acid (C24:0), nervonic acid (C24:1)